

This presentation and the accompanying slides (the "Presentation"), which have been prepared by Quick Heal Technologies Ltd. (the "Company"), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any securities, and shall not form the basis or be relied on in connection with any contract or binding commitment whatsoever. No offering of securities of the Company will be made except by means of a statutory offering document containing detailed information about the Company.

This Presentation has been prepared by the Company based on information and data which the Company considers reliable, but the Company makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this Presentation. This Presentation may not be all inclusive and may not contain all of the information that you may consider material. Any liability in respect of the contents of, or any omission from, this Presentation is expressly excluded.

This presentation contains certain forward-looking statements concerning the Company's future business prospects and business profitability, which are subject to a number of risks and uncertainties and the actual results could materially differ from those in such forward looking statements. The risks and uncertainties relating to these statements include, but are not limited to, risks and uncertainties regarding fluctuations in earnings, our ability to manage growth, competition (both domestic and international), economic growth in India and abroad, ability to attract and retain highly skilled professionals, time and cost over runs on contracts, our ability to manage our international operations, government policies and actions regulations, interest and other fiscal costs generally prevailing in the economy. The Company does not undertake to make any announcement in case any of these forward-looking statements become materially incorrect in future or update any forward-looking statements made from time to time by or on behalf of the Company.

Quick Heal acknowledges the ownership rights of third parties to the intellectual property rights mentioned in this document. Other logos/trademarks mentioned in the presentation belongs to respective owners and used only for reference purpose.







Agenda

01

02

03

04

05



Q4FY20 & FY20 Earnings Highlights



Company Overview



Industry Overview



The Quick Heal Advantage



Q4FY20 & FY20 Earnings



Q4FY20 & FY20 Earnings Highlights

Our FY 2020 financial performance was weakened due to slowdown in the economy which lead to credit crunch among MSME coupled with headwinds at our channel partners. The impact further worsened by COVID-19 pandemic which lead to lockdown in entire country



O4FY20 Revenue at


₹643 mln

down 25.3% from ₹ 860 mln in O4FY19

FY20 Revenue at

₹2,861 mln

down 9.1% from ₹ 3,149 mln in FY19





FY20 EBITDA at

₹914_{mln}

down 28.5%from ₹ 1,279 mln in FY19

EBITDA margin at

31.9%

in FY20 down 867bps from 40.6% in FY19

PAT

FY20 PAT at

₹744_{mln}

down 19.0% from ₹ 918 mln in FY19

PAT margin at

26.0%

In FY20 down 315bps from 29.2% in FY19

Average revenue per licences for FY20:

Retail at

₹518

Up 11.9% from FY19

Enterprise at

₹623

Up 10.3% from FY19

New enterprise customers with more than 500 users added in FY20:

200	Total
>=500 to <=999	61
>=1,000 to <=4,999	34
>=5,000	5



Company at a glance



Vision


To be the trusted global leader in securing the digital world

Mission

Secure our customers by providing innovative, most preferred and valued security solutions, services and knowledge

Protect information and interactions on all types of networks, devices & things globally

Build a healthy business and organization



Over 25 years of simplifying security

Scripting a new success story In the cyber security industry

Quick Heal





₹ 2,422 mln FY20 Revenue*







₹609 mln FY20 Revenue*




















- A "Make in India" product configured to secure countries, cities and companies
- Quick Heal undisputed leader in the retail segment
- Segrite making inroads in the SMB & enterprise segment
- Quick Heal Security Labs a team of highly efficient security researchers, analysts engineers leverages combination of AI, cloud and patented technologies deliver timely and advanced protection
- Solutions to secure across platforms

Shareholder information

Shareholding structure – 31st March 2020





Shareholder Information (as on 31st Mar 2020)


NSE Ticker	QUICKHEAL
BSE Ticker	539678
Market Cap (₹ mln)	5,217
% Free-float	27.17%
Free-float market cap (₹ mln)	1,417
Total Debt (₹ mln)	-
Cash & Cash Equivalents (₹ mln)	3,877
Enterprise Value (₹ mln)	1,340
Shares Outstanding	6,42,03,618
3M ADTV (Shares)	2,34,620
3M ADTV (₹ mln)	28.0
Industry	IT Software Products



2020 Cyber threat landscape shows that...







Source: Quick Heal Annual Threat Report 2020 Source: Segrite Threat Report 2020

...cyber-attacks continue to grow in scale and sophistication...

Detection statistics for Mobile Malware: 639K Per Day: 1,752 Per Hour: 73 Per Minute: 1.22 Adware: 125K Per Day: 344 Per Hour: 14 Per Minute: 0.24 Per Minute: 0.69





WHO reports five fold increase in cyber-attacks, urges vigilance

Cybercrime in India surges amid lockdown

India confirms malware attack at Kudankulam nuclear power plant

Over 3.13 lakh cybersecurity incidents reported till Oct. 2019: Minister

Amazon India admits to data breach affecting its sellers

Marriott discloses massive data breach affecting up to 500 million quests



The Average cost of a data breach in India.

An increase of **7.9%** from 2017

Source: PWC & DSCI report - Cybersecurity India Market

...together with rapid growth in India's digital adoption...

Growth In Country Digital Adoption Index % growth, 2014-17



China Russia & Germany

36% - Italy

35% - South Africa & France

31% - South Korea

30% - United Kingdom, Brazil & USA

27% - Sweden

25% - Canada & Australia

24% - Singapore

Source: McKinsey Institute – Digital India, March 2019



1.2b

People enrolled in the world's largest unique digital identity program





12.3b **Application** downloads



1.17b Wireless

phone subscribers



560m

Internet subscribers



354m

Smartphone devices



294m

Users engaged in social media

Digital usage in India is soaring as costs tumble

in 2018



lapan

26.2

Smartphones per 100 people in 2018 compared to 5.4 in 2014



560m

Internet users in 2018 compared to 239m in 2014



Cashless transaction per person in 2018 compared to 2.2 in 2014



8,320mb

Monthly data consumption per unique connection in 2018 compared to 86mb in 2014





0.1%

2014

Monthly data price (per 1gb as % of monthly GDP) in 2018 compared to 6.1% in 14

...is expected to increase Cybersecurity spending in India






15


Cybersecurity market in India is expected to grow at ~16% CAGR between 2019 to 2022 and become a \$3 bln market with security product market estimated to grow at ~17% to become \$1.6 bln market. Quick Heal is well placed to capitalise on this opportunity.

Source: PWC & DSCI report – Cyber Security India Market

Global cybersecurity market

along with cyber threat predictions for 2020






16


Source: Gartner Source: Segrite Threat Report 2020



Quick Heal is well positioned to leverage its strengths to capture the future opportunities



Strong threat detection and prevention capabilities...





Powers SIGNATURE-LESS and SIGNATURE-BASED detections


Our best and the most innovative malware hunting engine brings together the best of the best!












Research & Development leading to Innovations

25+ years of experience coupled with vast distribution network across India has helped us understand security market and issues faced by millions of users in depth which has led to consistent introduction of innovative products and solutions for our customers



Product Portfolio - Enterprise & Government




Product Portfolio - Home, SOHO & Mobile



Robust sales & distribution network in India

Sales Execution Robust pan India coverage **Complimentary support Metro Sales Coverage** from Quick Heal Strong presence across the Zonal and regional sales top metros in India. team to engage and support Coverage through T1 distributors and T2 resellers channel Landscape across Class B &C towns **Presence in Class A towns** Growing presence of T1 distributors Strong distribution across across B&C towns. Strong network of Class A towns backed by T2 T2 resellers - across Class B and Class resellers

QUICK HEAL Global Presence





Committed to deliver exceptional customer experience

- Multi-lingual end user support in English, Hindi and several other major regional Indian languages
 - Availability of data sheets, product videos and manuals on website for providing information on technical specifications, installation guide, upgrade mechanisms
 - Release of various articles, technical papers, quarterly threat reports and conducting webinars in the area of security software



Experienced Board of Directors



Dr. Kailash Katkar *MD & CEO*

Drives the strategic direction for the company while nurturing a strong leadership team to drive its execution



Dr. Sanjay Katkar Joint MD & CTO

Spearheads the creation and subsequent development of the core product technology



Mr. Shailesh Lakhani Non-Executive Director

Serves as the MD at Sequoia Capital India. Previously, he worked at Redknee's India subsidiary as the Managing Director



Mr. Amitabha Mukhopadhyay Independent Director

Over three decades of experience in corporate finance, legal and litigation, strategy and M&A. Served as the Group CFO of Thermax



Ms. Priti Rao Independent Director

Has 20+ years of diverse experience in building and delivering a range of IT services for customers Located across five continents



Mr. Mehul Savla Independent Director

Serves as Director for RippleWave Equity Advisors LLP. Previously worked at JP Morgan, ICICI Securities and SEBI



Ms. Apurva Joshi Independent Director

Certified bank forensic accounting professional and anti – money laundering expert

...along with strong Management...



Dr. Sanjay Katkar *Joint MD & CTO*

Co-founder of the Company

Leads the global technology strategy & is responsible for the core research & development of the products.

Has served as the Director of Association of Anti-Virus Researchers, Asia and is a distinguished speaker at various industry forums.

Holds Master's degree in Computer Science from the University of Pune.

Dr. Kailash Katkar *MD & CEO*

Co-founder of the Company

Has been the driving force in growing Quick Heal Technologies since it's inception.

A proven leader with a profound proficiency in developing strong client relationships, passion for building outstanding teams and a disciplined focus on operations & execution of strategy.

Mr. Nitin Kulkarni *CFO*

25+ years of experience in managing different aspects of finance in IT and Manufacturing Industry.

Previously held leadership positions at Tech Mahindra, KPIT, Atlas Copco India and Persistent Systems.

A member of the Institute of Chartered Accountants of India.

...and seasoned Leadership team



Ms. Reetu Raina Chief Human Resources Officer

Responsible for driving HR and steering the company's people operations, culture and recruitment initiatives.

Ms. Raina holds extensive industry experience and has worked across sectors such as Telecom, BFSI, and IT.

She has held leadership roles with domain-leading brands such as TATA, HDFC Bank, and Amdocs. She was the Head of HR at Sterlite Technologies.



Mr. Deepak Mishra Head, Retail Sales

Responsible for enhancing market share and driving channel strategy for the retail brand.

Has extensive exposure in sales and distribution, channel management, and building a robust distribution to drive productivity and profitability.

20 years of experience in FMCG, Beverages, Telecom and IT Industries.



Mr. Kuldeep Raina Head, Global Enterprise Sales

Responsible for leading the enterprise and government sales strategy and managing the vertical on a global level.

Passionate technocrat with a rich flare for sales and ability to drive targets in dynamic business environment.

20 years of diverse sales experience including leadership roles in cybersecurity companies.



Mr. Bijoe George Head, Global Marketing

Marketing strategist with over two decades of rich data-driven, integrated marketing experience.

Leading marketing transformation to deliver strategic value. Has extensive experience working on technology brands that include Cisco, HPE, Infosys, Citrix to name a few.

Bijoe loves the interplay between strategy, technology & creative while delivering results, big ideas and big wins.

Strong brand recognition...







Best Protection rate In AV-Comparatives Test 2018



Certified as
'Approved
Corporate Endpoint
Protection' for
Windows by
'AV-Test' 2018



Best cybersecurity brand award at National Summit on Digital Innovation & Cybersecurity Summit 2018



Quick Heal Technologies

Recognized by NASSCOM's DSCI as 'Cybersecurity Product Pioneer in India' 2019



Segrite

'Best Performance 2018' award for its Endpoint Security Solution from AV-Test Institute in Germany 2019



Quick Heal Technologies

Granted Patent for Anti-Ransomware Technology 2019 U.S. Patent No. US20160378988A1



Quick Heal Technologies

Granted Patent for its **Signatureless Behavior-based Detection Technology** 2019 U.S Patent No. US20170124327A1



Seqrite Endpoint Security

Certified as
'Approved
Corporate Endpoint
Protection' for
Windows
by 'AV-Test' 2019

...backed by Certifications, Patents and...

International & ISO Certifications

















Patented Technologies

USPTO 10,387,649

Signatureless Behaviour-based Detection Technology

USPTO 10,311,234

Anti-Ransomware technology

USPTO 8,973,136

System and method for protecting computer systems from malware attacks

USPTO 8,914,908

A completely automated computer implemented system and method for piracy control based on update requests

USPTO 8,347,389

System for protecting devices against virus attacks

USPTO 7,945,955

Virus detection in mobile devices having insufficient resources to execute virus detection software



Our marquee customers

























Trusted by over 9 million users across the world



Securing the future through our community initiatives

22,87,000+

Lives directly impacted since 2016



Cybersecurity

- Cybersecurity Awareness
- Securing Futures through secured programming







20,000+

Lives directly impacted since 2016



Education

- Life Skills Education
- Shaalangan Counselling Centre





2,500+

Lives impacted since 2016



Eradicating Extreme Hunger & Poverty

Project Disha works with Paud's Katkari Tribe









Quick Heal Academy to drive the next generation of cyber security experts



Popular Courses

- ✓ Cyber Security and Forensics
- ✓ Cyber Threat Intelligence
- ✓ Malware Analysis & Reverse Engineering
- √ Security Operations Centre (SOC)
- ✓ Electronic Crime Scene Investigation

Offerings



CORPORATE TRAINING



NEED-BASED TRAINING



WORKSHOPS & SEMINARS



CONNECTING CYBER ECO-SYSTEM

Academy Partners

Savitribai Phule Pune University

Designed 'M-Tech in Information Security' Program for Savitribai Phule Pune University

Quantum University

W

Quantum

丽

CHITKARA

MoU with Quantum University for a joint B.Tech (Hons.) with specialization in Cyber Security

Gujarat Forensic Sciences University

MoU with Gujarat Forensic Sciences University during Vibrant Gujarat 2017

Maharashtra Cosmopolitan Education Society

The society runs 30 institutes from its ultra modern campaigns located in Maharashtra

Chitkara University

MoU with Chitkara University Introduced an additional stream in Cyber Security for the four-year Undergraduate program


Deen Dayal Upadhyaya College

MoU with Deen Dayal Upadhyaya College, a constituent college of the University of Delhi






Q4FY20 - Consolidated Performance Highlights



Revenue was down 25.3% in Q4FY20 due to sudden lockdown in India which affected our distribution of products to our channel partners

FY20 - Consolidated Performance Highlights




Q4FY20 impact of COVID-19 impacted our yearly sales as historically Q4 is always our strong quarter in terms of revenue

36

* Cash PAT = PAT + Depreciation **As per Ind AS


Q4 & FY20 Segment Performance - Revenue break-up



Based on net revenues before adjusting for sales incentives

Q4FY20 Figures are low due to **COVID-19** impact

Q4 & FY20 Segment performance - Licenses Sold Analysis



Q4FY20 - Profitability statement

DADTICIII ADS / # malm)		Standalone			Consolidated	
PARTICULARS (₹ mln)	Q4FY19	Q4FY20	% change	Q4FY19	Q4FY20	% change
Total Revenue	853.54	634.31	-25.68%	860.01	642.54	-25.29%
Direct Cost	40.35	29.78		40.34	34.14	
Gross Profit	813.19	604.53	-25.66%	819.67	608.40	-25.78%
Gross Margin	95.27%	95.31%	+4bps	95.31%	94.69%	-62bps
Operating Cost						
Research and Development (R&D)	132.31	128.47		132.32	128.47	
Sales and Marketing (S&M)	193.12	234.67		198.11	238.58	
General Administration (G&A)	98.58	161.13		103.04	165.50	
Total Expenditure	424.01	524.27	-23.65%	433.46	532.55	-22.86%
EBITDA	389.18	80.26	-79.38%	386.21	75.85	-80.36%
EBITDA Margin	45.60%	12.65%	-3295bps	44.91%	11.80%	-3311bps
Depreciation	56.27	55.88		56.32	55.93	
EBIT	332.91	24.38	-92.68%	329.89	19.92	-93.96%
EBIT Margin	39.00%	3.84%	-3516bps	38.36%	3.10%	-3526bps
Other Income	84.80	81.12		85.15	82.42	
Profit Before Tax (PBT before exceptional items)	417.71	105.50	-74.74%	415.04	102.34	-75.34%
Exceptional Item	43.17	23.17		0.00	0.00	
Profit Before Tax (PBT after exceptional items)	374.54	82.33		415.04	102.34	
Tax	137.28	22.09		137.57	22.41	
Profit After Tax (PAT)	237.26	60.24	-74.61%	277.47	79.93	-71.19%
PAT Margin	27.80%	9.50%	-1830bps	32.26%	12.44%	-1982bps

FY20 - Profitability statement

DARTICIU ARC / # walm)		Standalone		C	Consolidated	
PARTICULARS (₹ mln)	FY19	FY20	% change	FY19	FY20	% change
Total Revenue	3,129.03	2,834.04	-9.43%	3,149.26	2,861.38	-9.14%
Direct Cost	153.23	111.75		151.50	124.13	
Gross Profit	2,975.80	2,722.29	-8.52%	2,997.76	2,737.25	-8.69%
Gross Margin	95.10%	96.06%	+96bps	95.19%	95.66%	+47bps
Operating Cost						
Research and Development (R&D)	541.47	532.90		541.47	532.90	
Sales and Marketing (S&M)	670.42	714.69		690.49	731.17	
General Administration (G&A)	469.77	543.90		486.79	559.26	
Total Expenditure	1,681.66	1,791.49	-6.53%	1,718.75	1,823.33	-6.08%
EBITDA	1,294.14	930.80	-28.08%	1,279.01	913.92	-28.54%
EBITDA Margin	41.36%	32.84%	-852bps	40.61%	31.94%	-867bps
Depreciation	235.27	216.64		235.49	216.77	
EBIT	1,058.87	714.16	-32.55%	1,043.52	697.15	-33.19%
EBIT Margin	33.84%	25.20%	-864bps	33.14%	24.36%	-878bps
Other Income	325.00	313.41		326.67	315.96	
Profit Before Tax (PBT before exceptional items)	1,383.87	1,027.57	-25.75%	1,370.19	1,013.11	-26.06%
Exceptional Item	93.17	23.17		0.00	0.00	
Profit Before Tax (PBT after exceptional items)	1,290.70	1,004.40		1,370.19	1,013.11	
Tax	451.06	268.01		451.95	269.00	
Profit After Tax (PAT)	839.64	736.39	-12.30%	918.24	744.11	-18.96%
PAT Margin	26.83%	25.98%	-85bps	29.16%	26.01%	-315bps

Q4FY20 - Ratio analysis

In %	Standalone		Consolidated	
	Q4FY19	Q4FY20	Q4FY19	Q4FY20
Expenses				
Direct Cost / Revenue	4.73%	4.69%	4.69%	5.31%
R&D / Revenue	15.50%	20.25%	15.39%	19.99%
S&M / Revenue	22.63%	37.00%	23.04%	37.13%
G&A / Revenue	11.55%	25.40%	11.98%	25.76%
Total Cost / Revenue	49.68%	82.65%	50.40%	82.88%
Margin				
Gross Margin	95.27%	95.31%	95.31%	94.69%
EBITDA	45.60%	12.65%	44.91%	11.80%
EBIT	39.00%	3.84%	38.36%	3.10%
PBT (Before Exceptional Item)	48.94%	16.63%	48.26%	15.93%
PBT (After Exceptional Item)	43.88%	12.98%	48.26%	15.93%
PAT	27.80%	9.50%	32.26%	12.44%

FY20 - Ratio analysis

I 0/	Standalone		Consolidated	
In %	FY19	FY20	FY19	FY20
Expenses				
Direct Cost / Revenue	4.90%	3.94%	4.81%	4.34%
R&D / Revenue	17.30%	18.80%	17.19%	18.62%
S&M / Revenue	21.43%	25.22%	21.93%	25.55%
G&A / Revenue	15.01%	19.19%	15.46%	19.55%
Total Cost / Revenue	53.74%	63.21%	54.58%	63.72%
Margin				
Gross Margin	95.10%	96.06%	95.19%	95.66%
EBITDA	41.36%	32.84%	40.61%	31.94%
EBIT	33.84%	25.20%	33.14%	24.36%
PBT (Before Exceptional Item)	44.23%	36.26%	43.51%	35.41%
PBT (After Exceptional Item)	41.25%	35.44%	43.51%	35.41%
PAT	26.83%	25.98%	29.16%	26.01%

Consolidated Balance Sheet

EQUITY AND LIABILITIES (₹ mln)	31 Mar 2019	31 Mar 2020
Share Holder's Funds:		
Equity Share Capital	705.63	642.03
Share application money pending allotment	0.17	-
Reserves and Surplus	7,191.79	5,798.65
Total Shareholder Funds	7,897.59	6,440.68
Non-Current Liabilities		
Net employee defined benefit liabilities	18.37	4.62
Other Non Current Liabilities	19.53	19.63
Total Non-Current Liabilities	37.90	24.25
Current Liabilities:		
Trade and Other Payables	387.87	387.27
Other Financial Liabilities	34.23	9.04
Other Current Liabilities	135.76	86.68
Net employee defined benefit liabilities	21.22	3.94
Current tax liabilities (Net)	13.70	13.80
Total Current Liabilities	592.78	500.73
Total Equity & Liabilities	8,528.27	6,965.66


ASSETS (₹ mln)	31 Mar 2019	31 Mar 2020
Non-Current Assets:		
Property, plant and equipment	1,570.04	1,485.09
Capital work-in-progress	106.33	34.00
Intangible assets	77.08	99.81
Non-current financial assets		
Investments in MF ,Tax-Free Bonds	296.23	353.32
Loan and Security Deposits	3.75	3.81
Bank Balances	4.04	3.91
Deferred tax assets (net)	86.69	25.86
Other non current assets	46.06	173.24
Total Non-Current Assets	2,190.22	2,179.04
Current assets:		
Inventories	53.94	62.40
Investment in Mutual Fund	3,602.17	2,745.22
Trade and other receivables	1,250.52	1,131.62
Bank Balances & Cash and Cash Equivalents	101.67	101.73
Investment in Fixed Deposit	1,247.33	698.52
Loan and security deposits	7.09	7.74
Interest accrued on FDR and Tax-Free Bonds	30.59	15.26
Other Current assets	44.74	24.13
Total Current Assets	6,338.05	4,786.62
Total Assets	8,528.27	6,965.66

Standalone Balance Sheet

EQUITY AND LIABILITIES (₹ mln)	31 Mar 2019	31 Mar 2020
Share Holder's Funds:		
Equity Share Capital	705.63	642.03
Share application money pending allotment	0.17	0.00
Reserves and Surplus	7,243.12	5,840.10
Total Shareholder Funds	7,948.92	6,482.13
Non-Current Liabilities		
Net employee defined benefit liabilities	18.37	4.62
Other Non Current Liabilities	19.53	19.63
Total Non-Current Liabilities	37.90	24.25
Current Liabilities:		
Trade and Other Payables	384.83	383.60
Other Financial Liabilities	34.23	9.04
Other Current Liabilities	131.49	83.79
Net employee defined benefit liabilities	21.12	3.94
Current tax liabilities (Net)	13.03	13.03
Total Current Liabilities	584.70	493.40
Total Equity & Liabilities	8,571.52	6,999.78

ASSETS (₹ mln)	31 Mar 2019	31 Mar 2020
Non-Current Assets:		
Property, plant and equipment	1,569.69	1,484.82
Capital work-in-progress	106.33	34.00
Intangible assets	76.86	99.61
Non-current financial assets		
Investments in MF & Tax-Free Bonds & Subsidiaries	406.53	453.96
Loan and Security Deposits	3.75	3.81
Bank Balances	4.04	3.91
Deferred tax assets (net)	86.69	25.86
Other non current assets	46.06	173.24
Total Non-Current Assets	2,299.95	2,279.21
Current assets:		
Inventories	41.41	62.19
Investment in Mutual Fund	3,602.17	2,745.22
Trade and other receivables	1,248.55	1,132.26
Bank Balances & Cash and Cash Equivalents	51.74	36.58
Investment in Fixed Deposit	1,247.33	698.52
Loan and security deposits	6.43	7.08
Interest accrued on FDR and Tax-Free Bonds	30.60	15.30
Other Current assets	43.34	23.42
Total Current Assets Total Assets	6,271.57 8,571.52	4,720.57 6,999.78

Working capital analysis




Receivable Days = [(Debtors/ Sales) X (366 days)]

Inventory Days = [(Inventory/Sales) X (366 days)]

Payable Days = [(Creditor/Sales) X (366 days)]

Calculation is based on net revenues before adjusting for sales incentives

Return ratio analysis



- > Company is continuously evaluating strategic inorganic opportunities to invest across the cybersecurity ecosystem
- > Till such time the company invests its surplus cash in mutual funds, tax free-bonds and fixed deposits

RoCE = EBIT / Avg. Capital Employed (Equity + Debt) **Cash Adj. RoCE** = EBIT / Avg. Cash Adj. Capital Employed (Equity + Debt – Cash & Cash Equivalents)

ROE = PAT / Avg. Equity

^{*} Calculated on trailing 12 months basis





Chief Financial Officer

Mr. Nitin Kulkarni
Nitin.Kulkarni@quickheal.co.in
+91-20-66813232

Company Secretary

Mr. Srinivas Anasingaraju cs@quickheal.co.in +91-20-66813232

CIN No: L72200MH1995PLC091408

www.quickheal.co.in

